Table 3.
Antibodies used for specific drug delivery to various types of cancer.
| Antibody | Drug | Application/Target | Linker | Ref. |
|---|---|---|---|---|
| Tumor vasculature | ||||
| anti-CD276 | pyrrolobenzo-diazepine | tumor vasculature in CD276+ tumors | maleimide linker | [182] |
| anti-TM4SF1 | auristatin (LP2) | TM4SF1+ tumor vasculature | noncleavable maleimido-caproyl | [183] |
| anti-PTK7 (PF-06647020) |
auristatin (Aur0101) | tumor initiating cells/tumor vasculature | protease-cleavable valine-citrulline | [184] |
| Breast cancer | ||||
| anti- HER2 (Trastuzumab) |
trastuzumab emtansine | Metastatic breast cancer | Protease-cleavable tetrapeptide linker | [185] |
| CR011 | monomethylauristatin E | breast cancer/glycoprotein NMB | Dipeptide | [186] |
| anti-LIV-1 (Ladiratuzumab) |
monomethyl auristatin E | Triple-negative breast cancer/LIV-1 | Protease-cleavable dipeptide | [187,188] |
| anti-Trop-2 (Sacituzumab) |
SN-38 | triple-negative breast cancer/Trop-2 | Hydrolysable link, with short polyethylene glycol moiety(CL2A) | [188,189] |
| Lymphoma | ||||
| anti-CD33 (gemtuzumab ozogamicin) |
calicheamicin | acute myeloid lymphoma | Acid-labile (N-acyl hydrazine) | [190] |
| anti-CD30 (brentuximab vedotin) |
monomethyl auristatinE (MMAE) | relapsed Hodgkin’s lymphoma/ anaplastic large cell lymphoma | cathepsin cleavable | [190] |
| Neurological cancer | ||||
| anti-EGFR (depatuxizumab mafodotin) |
monomethyl auristatinF (MMAF) | glioblastoma | noncleavable maleimido-caproyl | [190] |
| anti-ALK (CDX-0125-TEI) |
thienoindole (NMS-P945 | human neuroblastoma xenograft in mice neuroblastomas | dipeptidic/cleavable | [191] |
| Other | ||||
| anti–PD-L1 (MPDL3280A) |
- | inhibit PD-L1 interactions with both PD-1 and B7-1 (f.e. metastatic bladder cancer) | - | [192] |
| Anti-AXL (enapotamab vedotin) |
monomethyl auristatinE (MMAE) | non-small lung cancer, ovarian, cervical, endometrial, thyroid, melanoma | Protease-cleavable valine-citruline | [190,193] |
| anti-PSMA (MEDI3726) |
pyrrolobenzo-diazepine | Metastatic prostate cancer | cathepsin cleavable | [190,194] |